Vertex Pharmaceuticals Inc. said collaborator GlaxoSmithKline plc is likely to file for approval of the HIV protease inhibitor GW433908 - which last month entered its third pivotal Phase III trial - by the end of the year in the U.S. and Europe. (BioWorld Today)

The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against Stage IV metastatic breast cancer was enough to feed another round in the sporadic, ongoing debate over angiogenesis inhibitors. (BioWorld Financial Watch)

Erectile dysfunction (ED) used to be called impotence, until doctors decided on what the Merck Manual of Diagnosis and Therapy refers to as a "less pejorative" and more specific phrase. (BioWorld Financial Watch)